Celltrion, Inc. (068270.KS)
Makes affordable copycat versions of expensive biologic medicines for diseases like cancer and arthritis.
180,000.00+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+10.3%
The outlook
Celltrion trades near the upper end of its 52-week range, with analyst consensus solidly bullish and an average price target about 47% above current levels. The stock shows mixed momentum relative to its moving averages, though overall sentiment leans constructive based on analyst coverage and target positioning.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 24 analysts
Price trendMixed vs its moving averages
52-week range75% of the way from its 52-week low to high
Price targetAvg target +47% vs current price
Analyst price target
~12-month · 24 analysts265,216.28average target+47.3% vs now
Now 180,000.00
Low 200,000.00High 330,000.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$41.28T
52-wk high
239,047.62
52-wk low
0.00
50-day avg
175,076.67
200-day avg
186,869.17
Trailing P/E
—